Cite
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
MLA
Ferdinand W. N. M. Wit, et al. “Increased Risk of Lipodystrophy When Nucleoside Analogue Reverse Transcriptase Inhibitors Are Included with Protease Inhibitors in the Treatment of HIV-1 Infection.” AIDS, May 2001, pp. 847–55. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7ce311c0eed3cc5023f80753365eb751&authtype=sso&custid=ns315887.
APA
Ferdinand W. N. M. Wit, Elisabeth H. Gisolf, A. Japour, G. J. Weverling, Peter Reiss, M. van der Valk, & S. A. Danner. (2001). Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS, 847–855.
Chicago
Ferdinand W. N. M. Wit, Elisabeth H. Gisolf, A. Japour, G. J. Weverling, Peter Reiss, M. van der Valk, and S. A. Danner. 2001. “Increased Risk of Lipodystrophy When Nucleoside Analogue Reverse Transcriptase Inhibitors Are Included with Protease Inhibitors in the Treatment of HIV-1 Infection.” AIDS, May, 847–55. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7ce311c0eed3cc5023f80753365eb751&authtype=sso&custid=ns315887.